May 5, 2022 02:04 PM EDT
Pharma
Manufacturing

Two No­var­tis sites stop man­u­fac­tur­ing can­cer ther­a­pies af­ter qual­i­ty is­sues

Josh Sullivan

Af­ter find­ing some qual­i­ty is­sues at­trib­uted to its man­u­fac­tur­ing process, No­var­tis has halt­ed the pro­duc­tion of two of its ra­di­oli­gand ther­a­pies …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times